FDA Clearance Tracker · P220023
Paradise® Ultrasound Renal Denervation System
Last checked: Nov 19, 2026Latest source record: Nov 7, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Nov 7, 2023
Approved
Time to decision
378 days
Received Oct 25, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P220023
- Device name
- Paradise® Ultrasound Renal Denervation System
- Applicant
- Recor Medical, Inc.
- Applicant location
- Palo Alto, CA
- Received
- Oct 25, 2022
- Decided
- Nov 7, 2023
- Decision
- Approved
- Supplements
- 11 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Ablation catheter, renal denervation (QYI)
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
The Paradise Ultrasound Renal Denervation System is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QYI (Ablation catheter, renal denervation).
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
Other decisions for Recor Medical, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.